Aug 17, 2023 8:00am EDT Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Jun 21, 2023 7:00am EDT Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
May 22, 2023 8:00am EDT Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 21, 2023 8:00am EDT Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 10, 2023 7:00am EDT Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 04, 2023 8:00am EDT Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
May 02, 2023 4:30pm EDT Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Apr 17, 2023 8:00am EDT Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alfa (PRS-343) At 2023 AACR Annual Meeting
